Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The compounds can also be co-administered with leptin or a leptin analog.

Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The compounds can also be co-administered with leptin or a leptin analog.

This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.

This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.

A pharmaceutical compound for the treatment of obesity related disorder that is a conjugate of myristic acid and a leptin-related peptide. Preferably, the leptin-related peptide is OB3 that has been D-substituted at Leu-4. The resulting conjugate significantly improved the pharmacokinetic profile of the leptin-related peptide by extending its half-life from less than one hour to as long as twenty-eight hours, depending on the route of delivery, increasing uptake, reducing the rate of plasma clearance, and enabling the minimal effective dose to be reduced several fold.

Devices and methods for treating ischemia and reperfusion injury (IRI) are configured for sustained-release of anti-proliferative drug into the wall of a blood vessel (to prevent in-stent stenosis), and for sustained-release of leptin antagonist into the lumen to be carried by the blood and be uptaken by tissue cells that were subjected to IRI.

Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

This invention provides for a compound of formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

The present invention relates to a protein conjugate in which a physiologically active polypeptide and a biocompatible material are linked through a fatty acid derivative, thus having an extended duration of physiological activity compared to that of a natural type, and a method of preparing the same. The protein conjugate of the present invention in which a biocompatible material, fatty acid, and a physiologically active polypeptide are linked was confirmed to have an increased half-life of the physiologically active polypeptide, and thus can be widely used in the field of protein drugs.